<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Antiviral Agents Screening of Natural Extracts for Inhibitors against" exact="Japanese Encephalitis" post="Virus Infection Ouabain Blocks JEV Infection Guo et al."/>
 <result pre="Antiviral Agents Screening of Natural Extracts for Inhibitors against Japanese" exact="Encephalitis" post="Virus Infection Ouabain Blocks JEV Infection Guo et al."/>
 <result pre="Screening of Natural Extracts for Inhibitors against Japanese Encephalitis Virus" exact="Infection" post="Ouabain Blocks JEV Infection Guo et al. GuoJiaoabJiaXiaoyingabLiuYangaWangShaoboab*CaoJunyuanabhttps://orcid.org/0000-0002-8895-3679ZhangBoabXiaoGengfuabhttps://orcid.org/0000-0002-8696-9773WangWeiab[a], State"/>
 <result pre="for Inhibitors against Japanese Encephalitis Virus Infection Ouabain Blocks JEV" exact="Infection" post="Guo et al. GuoJiaoabJiaXiaoyingabLiuYangaWangShaoboab*CaoJunyuanabhttps://orcid.org/0000-0002-8895-3679ZhangBoabXiaoGengfuabhttps://orcid.org/0000-0002-8696-9773WangWeiab[a], State Key Laboratory of Virology,"/>
 <result pre="Wang W. 2020. Screening of natural extracts for inhibitors against" exact="Japanese encephalitis" post="virus infection. Antimicrob Agents Chemother 64:e02373-19. https://doi.org/10.1128/AAC.02373-19. epreprint: 2019-12-12epub:"/>
 <result pre="W. 2020. Screening of natural extracts for inhibitors against Japanese" exact="encephalitis" post="virus infection. Antimicrob Agents Chemother 64:e02373-19. https://doi.org/10.1128/AAC.02373-19. epreprint: 2019-12-12epub:"/>
 <result pre="2020. Screening of natural extracts for inhibitors against Japanese encephalitis" exact="virus infection." post="Antimicrob Agents Chemother 64:e02373-19. https://doi.org/10.1128/AAC.02373-19. epreprint: 2019-12-12epub: 2020-2-2collection: 2020-3pmc-release:"/>
 <result pre="of the Creative Commons Attribution 4.0 International license.AAC.02373-19.pdf The mosquito-borne" exact="Japanese encephalitis" post="virus (JEV) causes serious illness worldwide that is associated"/>
 <result pre="the Creative Commons Attribution 4.0 International license.AAC.02373-19.pdf The mosquito-borne Japanese" exact="encephalitis" post="virus (JEV) causes serious illness worldwide that is associated"/>
 <result pre="approach to discover potential antiviral agents. Abstract ABSTRACT The mosquito-borne" exact="Japanese encephalitis" post="virus (JEV) causes serious illness worldwide that is associated"/>
 <result pre="to discover potential antiviral agents. Abstract ABSTRACT The mosquito-borne Japanese" exact="encephalitis" post="virus (JEV) causes serious illness worldwide that is associated"/>
 <result pre="and digoxin, were identified as having robust efficiency against JEV" exact="infection" post="with the selectivity indexes over 1,000. The results indicated"/>
 <result pre="The results indicated that ouabain and digoxin blocked the JEV" exact="infection" post="at the replication stage by targeting the Na+/K+-ATPase. Furthermore,"/>
 <result pre="developed as an effective anti-JEV drug. KEYWORDS high-content screening (HCS)" exact="Japanese encephalitis" post="virus (JEV) ouabain digoxin Na+/K+-ATPase Funding National Key Research"/>
 <result pre="as an effective anti-JEV drug. KEYWORDS high-content screening (HCS) Japanese" exact="encephalitis" post="virus (JEV) ouabain digoxin Na+/K+-ATPase Funding National Key Research"/>
 <result pre="China (NSF)https://doi.org/10.13039/501100001809 31670165WangWei fig-count: table-count: equation-count: ref-count: page-count: word-count: INTRODUCTION" exact="Japanese encephalitis" post="virus (JEV) is a member of the genus Flavivirus"/>
 <result pre="(NSF)https://doi.org/10.13039/501100001809 31670165WangWei fig-count: table-count: equation-count: ref-count: page-count: word-count: INTRODUCTION Japanese" exact="encephalitis" post="virus (JEV) is a member of the genus Flavivirus"/>
 <result pre="FDA-approved compounds, ouabain and digoxin, were identified to inhibit JEV" exact="infection" post="both in vitro and in vivo. The results of"/>
 <result pre="to contribute to our understanding of the biology of JEV" exact="infection" post="and provide novel host targets for the development of"/>
 <result pre="HCS assay conditions. The HCS assay-optimized conditions contain cell density," exact="infective" post="dose, and assay endpoint. The assay conditions for HCS"/>
 <result pre="density of 10,000 cells per 96-well plate, a multiplicity of" exact="infection" post="(MOI) of 0.8, and an endpoint of 24 h"/>
 <result pre="their solubility in dimethyl sulfoxide (DMSO) at room temperature and" exact="absence of" post="any obvious cytotoxicity on Vero cells. Compounds (50 μM) that"/>
 <result pre="of &amp;gt;1,917 and &amp;gt;969.9, respectively. FIG 1 HCS for inhibitors of JEV" exact="infection" post="using the natural extracts library. (A) HCS assay timeline."/>
 <result pre="(C) HCS of a library of 1,034 natural extracts for" exact="primary" post="candidates inhibiting JEV infection. Each dot represents the percent"/>
 <result pre="and digoxin in different cell lines and viruses. For AT31" exact="infection" post="of Vero cells, digoxin (392 nM) and ouabain (196 nM) displayed"/>
 <result pre="(A and B) Immunofluorescence staining assay (IFA) images showing the" exact="viral" post="protein (green) and nuclei (blue) are displayed. (C and"/>
 <result pre="groups were all above 40%, indicating a strong inhibition of" exact="viral" post="replication (Fig. 3D and F). Further, the inhibitory effect"/>
 <result pre="the inhibitory effect of two compounds on AT31 and SA14" exact="infection" post="was also evaluated in Huh-7 cells and U251 cells."/>
 <result pre="JEV-infected Vero cells, plaque assays were performed to detect the" exact="viral" post="titer, and a dose-dependent anti-JEV effect was similarly observed"/>
 <result pre="lines (Fig. 3G to J). Ouabain and digoxin inhibit JEV" exact="infection" post="during viral RNA synthesis. To determine the cellular process"/>
 <result pre="3G to J). Ouabain and digoxin inhibit JEV infection during" exact="viral" post="RNA synthesis. To determine the cellular process that these"/>
 <result pre="digoxin exerted full inhibitory effects on JEV infection, suggesting that" exact="viral" post="replication was the main stage at which these drugs"/>
 <result pre="translation of replicon RNA, confirming that these drugs inhibit JEV" exact="infection" post="at the replication stage. JEV inhibition with ouabain and"/>
 <result pre="JEV-infected group succumbed to the infection. Ouabain treatment following JEV" exact="infection" post="increased the survival rate to nearly 60% (8 out"/>
 <result pre="survival curves (n = 14 to 15 for each group). (B) The" exact="viral" post="loads in mouse brains were measured by plaque assay"/>
 <result pre="such as meningitis, perivascular cuffing, and glial nodules. (D) The" exact="viral" post="loads in brain, blood, and spleen were measured by"/>
 <result pre="P &amp;lt; 0.01; *, P &amp;lt; 0.05. To further relate these protective effects to" exact="viral" post="load and histopathological changes in mouse brains, the viral"/>
 <result pre="to viral load and histopathological changes in mouse brains, the" exact="viral" post="titer was determined and mouse brain sections were collected"/>
 <result pre="during the progression of the disease, ouabain treatment significantly reduced" exact="viral" post="load in infected mice compared to untreated infected mice."/>
 <result pre="of histopathological changes is accompanied by a reduction in the" exact="viral" post="load as well as a reduction in mortality rate,"/>
 <result pre="mortality rate, further confirming the curative effects of ouabain on" exact="viral encephalitis." post="The viral loads of brain, blood, and spleen were"/>
 <result pre="confirming the curative effects of ouabain on viral encephalitis. The" exact="viral" post="loads of brain, blood, and spleen were also evaluated"/>
 <result pre="infection. As shown in Fig. 6D, on day 1 postinfection," exact="viral" post="titers in the brain were almost undetectable, and ouabain"/>
 <result pre="brain were almost undetectable, and ouabain exhibited little effect on" exact="viral" post="titers in the brain at the preclinical stage. Accordingly,"/>
 <result pre="the preclinical stage. Accordingly, ouabain had little effect on decreasing" exact="viral" post="titers in the blood and spleen at the earlier"/>
 <result pre="time points, which was mostly due to that the detectable" exact="viral" post="genome copy numbers were too low to be comparable."/>
 <result pre="results indicate that ouabain could alleviate histopathological changes and reduce" exact="viral" post="loads in the brain, thus protecting mice against JEV-induced"/>
 <result pre="JEV-induced lethality and confirming the curative effects of ouabain on" exact="viral encephalitis." post="DISCUSSION JEV continues to spread in Asia and other"/>
 <result pre="calcium blocker using in the treatment of hypertension, inhibited JEV" exact="infection" post="in vitro and in vivo (11). Similarly, Fang et"/>
 <result pre="and found that FGIN-1-27, an anxiolytic drug that targets the" exact="peripheral" post="benzodiazepine receptor, reduced the JEV infection in vitro (15)."/>
 <result pre="drug that targets the peripheral benzodiazepine receptor, reduced the JEV" exact="infection" post="in vitro (15). Drug screening and repurposing has become"/>
 <result pre="high-content screening assay design could identify compounds that inhibit JEV" exact="viral" post="entry, translation, and RNA synthesis. In this study, eight"/>
 <result pre="been proven to be effective in inhibiting flavivirus or HCV" exact="infections" post="via different mechanisms (16–20). These results demonstrate that our"/>
 <result pre="viruses such as human cytomegalovirus, positive-sense RNA viruses such as" exact="chikungunya" post="virus, and negative-sense RNA viruses such as lymphocytic choriomeningitis"/>
 <result pre="such as chikungunya virus, and negative-sense RNA viruses such as" exact="lymphocytic choriomeningitis" post="virus (LCMV) (21–25). Notably, we have tried to select"/>
 <result pre="antiviral effects by targeting the cellular protein other than the" exact="viral" post="protein, making the barrier to resistance more difficult to"/>
 <result pre="protein, making the barrier to resistance more difficult to overcome." exact="Cardiac" post="glycoside acts via inhibiting the sodium-potassium ion pump, leading"/>
 <result pre="(26). In this study, ouabain exhibited therapeutic effects on JEV" exact="infection" post="in an adult mouse model by decreasing viral loads"/>
 <result pre="study, ouabain exhibited therapeutic effects on JEV infection in an" exact="adult" post="mouse model by decreasing viral loads and alleviating pathological"/>
 <result pre="on JEV infection in an adult mouse model by decreasing" exact="viral" post="loads and alleviating pathological injuries in the brain, which"/>
 <result pre="contribute to the antiviral effects. First, ouabain may block JEV" exact="infection" post="by inducing the cellular stress response. Ouabain treatment in"/>
 <result pre="differentiation, which stimulate an antiviral state that might block JEV" exact="infection" post="in the end (30). Second, JEV could replicate in"/>
 <result pre="in the end (30). Second, JEV could replicate in the" exact="central nervous system" post="(CNS), and infections result in the breakdown of the"/>
 <result pre="JEV could replicate in the central nervous system (CNS), and" exact="infections" post="result in the breakdown of the blood-brain barrier (BBB)"/>
 <result pre="system (CNS), and infections result in the breakdown of the" exact="blood-brain barrier" post="(BBB) along with an influx of inflammatory cells; the"/>
 <result pre="of inflammatory cells; the breakdown of BBB caused by JEV" exact="infection" post="may have allowed BBB-nonpermissive ouabain to enter the brain,"/>
 <result pre="the murine ATPase α2 and α3 isoforms (31), and inhibit" exact="viral" post="replication in neurons. Together, these findings provide valuable information"/>
 <result pre="JEV AT31 and SA14 strains were generated by using the" exact="infectious" post="clones of pMWJEAT-AT31 (kindly provided by T. Wakita, Tokyo"/>
 <result pre="(GenBank accession no. U14163) as previously described (32), respectively. The" exact="infectious" post="clone plasmids were linearized, subjected to in vitro transcription,"/>
 <result pre="BHK-21 cells. Optimization of HCS assay conditions. The cell density," exact="infective" post="dose, and assay endpoint were optimized for the HCS"/>
 <result pre="to 72 h) after JEV inoculation. The appropriate cell density," exact="infective" post="dose, and assay endpoint for the HCS assay were"/>
 <result pre="the same wells. After an additional 23 h of incubation," exact="infection" post="was stopped by rinsing each well once with phosphate-buffered"/>
 <result pre="blocked with 5% FBS (Gibco), followed by treatment with the" exact="primary" post="antibody anti-JEV prM (full-length prM was expressed in Escherichia"/>
 <result pre="according to the following: preinfection (−1 to 0 h), during" exact="infection" post="(0 to 1 h), and postinfection (1 to 24"/>
 <result pre="for 1 h, and the mixtures were diluted 100-fold before" exact="infection" post="of Vero cells. Virus titers were determined by plaque"/>
 <result pre="triplicate repeat experiments. Antiviral efficacy of ouabain in BALB/c mice." exact="Adult" post="male BALB/c mice (4 weeks) were randomly divided into three"/>
 <result pre="plaque assay, qRT-PCR, and histopathology investigation (Vectra ss; PerkinElmer). The" exact="viral" post="burden was determined by plaque assay. The samples were"/>
 <result pre="at 4°C) for 15 min and then diluted serially prior to" exact="infection" post="of BHK-21 cells. The viral titer was adjusted for"/>
 <result pre="then diluted serially prior to infection of BHK-21 cells. The" exact="viral" post="titer was adjusted for sample volume and tissue weight"/>
 <result pre="on ABI Real-Time PCR systems using standard cycling conditions. The" exact="viral" post="burden was calculated on a standard curve produced using"/>
 <result pre="curve produced using serial 10-fold dilutions of plasmids carrying the" exact="infectious" post="clone. For histopathology investigation, brain tissues were collected from"/>
 <result pre="the virus and vaccines. Hum Vaccin Immunother10:263–279. doi:10.4161/hv.26902.24161909 2.EndyTP, NisalakA2002Japanese" exact="encephalitis" post="virus: ecology and epidemiology. Curr Top Microbiol Immunol267:11–48. doi:10.1007/978-3-642-59403-8_2.12082986"/>
 <result pre="ecology and epidemiology. Curr Top Microbiol Immunol267:11–48. doi:10.1007/978-3-642-59403-8_2.12082986 3.MisraUK, KalitaJ2010Overview:" exact="Japanese encephalitis." post="Prog Neurobiol91:108–120. doi:10.1016/j.pneurobio.2010.01.008.20132860 4.ErlangerTE, WeissS, KeiserJ, UtzingerJ, WiedenmayerK2009Past, present,"/>
 <result pre="doi:10.1016/j.pneurobio.2010.01.008.20132860 4.ErlangerTE, WeissS, KeiserJ, UtzingerJ, WiedenmayerK2009Past, present, and future of" exact="Japanese encephalitis." post="Emerg Infect Dis15:1–7. doi:10.3201/eid1501.080311.19116041 5.GhoshD, BasuA, BrookerS2009Japanese encephalitis—a pathological"/>
 <result pre="and clinical perspective. PLoS Negl Trop Dis3:e437. doi:10.1371/journal.pntd.0000437.19787040 6.TurtleL, SolomonT2018Japanese" exact="encephalitis" post="— the prospects for new treatments. Nat Rev Neurol14:298–313."/>
 <result pre="Virol76:3596–3604. doi:10.1128/jvi.76.8.3596-3604.2002.11907199 8.ChangCC, OuYC, RaungSL, ChenCJ2005Antiviral effect of dehydroepiandrosterone on" exact="Japanese encephalitis" post="virus infection. J Gen Virol86:2513–2523. doi:10.1099/vir.0.81123-0.16099910 9.SebastianL, DesaiA, ShampurMN,"/>
 <result pre="doi:10.1128/jvi.76.8.3596-3604.2002.11907199 8.ChangCC, OuYC, RaungSL, ChenCJ2005Antiviral effect of dehydroepiandrosterone on Japanese" exact="encephalitis" post="virus infection. J Gen Virol86:2513–2523. doi:10.1099/vir.0.81123-0.16099910 9.SebastianL, DesaiA, ShampurMN,"/>
 <result pre="8.ChangCC, OuYC, RaungSL, ChenCJ2005Antiviral effect of dehydroepiandrosterone on Japanese encephalitis" exact="virus infection." post="J Gen Virol86:2513–2523. doi:10.1099/vir.0.81123-0.16099910 9.SebastianL, DesaiA, ShampurMN, PerumalY, SriramD,"/>
 <result pre="PerumalY, SriramD, VasanthapuramR2008N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of" exact="Japanese encephalitis" post="virus infection in vitro and in vivo. Virol J5:64."/>
 <result pre="SriramD, VasanthapuramR2008N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese" exact="encephalitis" post="virus infection in vitro and in vivo. Virol J5:64."/>
 <result pre="VasanthapuramR2008N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis" exact="virus infection" post="in vitro and in vivo. Virol J5:64. doi:10.1186/1743-422X-5-64.18498627 10.ChangSJ,"/>
 <result pre="derivative (SCH 16) is an inhibitor of Japanese encephalitis virus" exact="infection" post="in vitro and in vivo. Virol J5:64. doi:10.1186/1743-422X-5-64.18498627 10.ChangSJ,"/>
 <result pre="activity of Isatis indigotica extract and its derived indirubin against" exact="Japanese encephalitis" post="virus. Evid Based Complement Alternat Med2012:925830. doi:10.1155/2012/925830.22911608 11.WangS, LiuY,"/>
 <result pre="of Isatis indigotica extract and its derived indirubin against Japanese" exact="encephalitis" post="virus. Evid Based Complement Alternat Med2012:925830. doi:10.1155/2012/925830.22911608 11.WangS, LiuY,"/>
 <result pre="WangP, ZhangL, XiaoG, WangW2017Screening of FDA-approved drugs for inhibitors of" exact="Japanese encephalitis" post="virus infection. J Virol91:e01055-17. doi:10.1128/JVI.01055-17.28814523 12.NawaM, TakasakiT, YamadaK, KuraneI,"/>
 <result pre="ZhangL, XiaoG, WangW2017Screening of FDA-approved drugs for inhibitors of Japanese" exact="encephalitis" post="virus infection. J Virol91:e01055-17. doi:10.1128/JVI.01055-17.28814523 12.NawaM, TakasakiT, YamadaK, KuraneI,"/>
 <result pre="XiaoG, WangW2017Screening of FDA-approved drugs for inhibitors of Japanese encephalitis" exact="virus infection." post="J Virol91:e01055-17. doi:10.1128/JVI.01055-17.28814523 12.NawaM, TakasakiT, YamadaK, KuraneI, AkatsukaT2003Interference in"/>
 <result pre="infection. J Virol91:e01055-17. doi:10.1128/JVI.01055-17.28814523 12.NawaM, TakasakiT, YamadaK, KuraneI, AkatsukaT2003Interference in" exact="Japanese encephalitis" post="virus infection of Vero cells by a cationic amphiphilic"/>
 <result pre="J Virol91:e01055-17. doi:10.1128/JVI.01055-17.28814523 12.NawaM, TakasakiT, YamadaK, KuraneI, AkatsukaT2003Interference in Japanese" exact="encephalitis" post="virus infection of Vero cells by a cationic amphiphilic"/>
 <result pre="Virol91:e01055-17. doi:10.1128/JVI.01055-17.28814523 12.NawaM, TakasakiT, YamadaK, KuraneI, AkatsukaT2003Interference in Japanese encephalitis" exact="virus infection" post="of Vero cells by a cationic amphiphilic drug, chlorpromazine."/>
 <result pre="doi:10.1128/JVI.01055-17.28814523 12.NawaM, TakasakiT, YamadaK, KuraneI, AkatsukaT2003Interference in Japanese encephalitis virus" exact="infection" post="of Vero cells by a cationic amphiphilic drug, chlorpromazine."/>
 <result pre="SunL, WangY, ZohaibA, DongQ, RuanX, SongY, HeW, ChenH, CaoS2014Etanercept reduces" exact="neuroinflammation" post="and lethality in mouse model of Japanese encephalitis. J"/>
 <result pre="ChenH, CaoS2014Etanercept reduces neuroinflammation and lethality in mouse model of" exact="Japanese encephalitis." post="J Infect Dis210:875–889. doi:10.1093/infdis/jiu179.24652493 14.MishraMK, BasuA2008Minocycline neuroprotects, reduces microglial"/>
 <result pre="BasuA2008Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and" exact="viral" post="replication following Japanese encephalitis. J Neurochem105:1582–1595. doi:10.1111/j.1471-4159.2008.05238.x.18208541 15.FangJ, SunL,"/>
 <result pre="microglial activation, inhibits caspase 3 induction, and viral replication following" exact="Japanese encephalitis." post="J Neurochem105:1582–1595. doi:10.1111/j.1471-4159.2008.05238.x.18208541 15.FangJ, SunL, PengG, XuJ, ZhouR, CaoS,"/>
 <result pre="XuJ, ZhouR, CaoS, ChenH, SongY2013Identification of three antiviral inhibitors against" exact="Japanese encephalitis" post="virus from library of pharmacologically active compounds 1280. PLoS"/>
 <result pre="ZhouR, CaoS, ChenH, SongY2013Identification of three antiviral inhibitors against Japanese" exact="encephalitis" post="virus from library of pharmacologically active compounds 1280. PLoS"/>
 <result pre="conserved inhibitory mechanism of a lycorine derivative against enterovirus and" exact="hepatitis" post="C virus. Antimicrob Agents Chemother60:913–924. doi:10.1128/AAC.02274-15.26596952 17.ZouG, Puig-BasagoitiF, ZhangB,"/>
 <result pre="KoharaM, BenjellounS, KinoY, InoueK, MatsumoriA, Tsukiyama-KoharaK2015Inhibitory effects of Pycnogenol(R) on" exact="hepatitis" post="C virus replication. Antiviral Res113:93–102. doi:10.1016/j.antiviral.2014.10.017.25446333 19.FauvelleC, LambotinM, HeydmannL,"/>
 <result pre="19.FauvelleC, LambotinM, HeydmannL, PrakashE, BhaskaranS, VishwaramanM, BaumertTF, MoogC2017A cinnamon-derived procyanidin" exact="type A" post="compound inhibits hepatitis C virus cell entry. Hepatol Int11:440–445."/>
 <result pre="BhaskaranS, VishwaramanM, BaumertTF, MoogC2017A cinnamon-derived procyanidin type A compound inhibits" exact="hepatitis" post="C virus cell entry. Hepatol Int11:440–445. doi:10.1007/s12072-017-9809-y.28698985 20.BatistaMN, BragaACS,"/>
 <result pre="CaiY, KuhnJH, YatesJR3rd, TorbettBE, de la TorreJC2018Interactome analysis of the" exact="lymphocytic choriomeningitis" post="virus nucleoprotein in infected cells reveals ATPase Na+/K+ transporting"/>
 <result pre="virus nucleoprotein in infected cells reveals ATPase Na+/K+ transporting subunit" exact="Alpha" post="1 and prohibitin as host-cell factors involved in the"/>
 <result pre="24.HawmanDW, FoxJM, AshbrookAW, MayNA, SchroederKMS, TorresRM, CroweJEJr, DermodyTS, DiamondMS, MorrisonTE2016Pathogenic" exact="chikungunya" post="virus evades B cell responses to establish persistence. Cell"/>
 <result pre="SilvaLA, MayNA, BauerJA, MorrisonTE, DermodyTS2016Antagonism of the sodium-potassium ATPase impairs" exact="chikungunya" post="virus infection. mBio7:e00693-16. doi:10.1128/mBio.00693-16.27222471 26.XieZ, AskariA2002Na(+)/K(+)-ATPase as a signal"/>
 <result pre="MayNA, BauerJA, MorrisonTE, DermodyTS2016Antagonism of the sodium-potassium ATPase impairs chikungunya" exact="virus infection." post="mBio7:e00693-16. doi:10.1128/mBio.00693-16.27222471 26.XieZ, AskariA2002Na(+)/K(+)-ATPase as a signal transducer. Eur"/>
 <result pre="LiSH, CaoSB, YuanZM, ShiPY, QinCF, ZhangB2014Recovery of a chemically synthesized" exact="Japanese encephalitis" post="virus reveals two critical adaptive mutations in NS2B and"/>
 <result pre="CaoSB, YuanZM, ShiPY, QinCF, ZhangB2014Recovery of a chemically synthesized Japanese" exact="encephalitis" post="virus reveals two critical adaptive mutations in NS2B and"/>
 <result pre="the E protein: implications for understanding the entry mechanism of" exact="Japanese encephalitis" post="virus. J Virol89:5668–5686. doi:10.1128/JVI.00293-15.25762738 34.MutsoM, SaulS, RausaluK, SusovaO, ZusinaiteE,"/>
 <result pre="E protein: implications for understanding the entry mechanism of Japanese" exact="encephalitis" post="virus. J Virol89:5668–5686. doi:10.1128/JVI.00293-15.25762738 34.MutsoM, SaulS, RausaluK, SusovaO, ZusinaiteE,"/>
 <result pre="34.MutsoM, SaulS, RausaluK, SusovaO, ZusinaiteE, MahalingamS, MeritsA2017Reverse genetic system, genetically" exact="stable" post="reporter viruses and packaged subgenomic replicon based on a"/>
 <result pre="stable reporter viruses and packaged subgenomic replicon based on a" exact="Brazilian" post="Zika virus isolate. J Gen Virol98:2712–2724. doi:10.1099/jgv.0.000938.29022864 35.ChenL, LiuY,"/>
 <result pre="of peptide inhibitors derived from the protein E stem against" exact="Japanese encephalitis" post="and Zika viruses. Antiviral Res141:140–149. doi:10.1016/j.antiviral.2017.02.009.28232248"/>
 <result pre="peptide inhibitors derived from the protein E stem against Japanese" exact="encephalitis" post="and Zika viruses. Antiviral Res141:140–149. doi:10.1016/j.antiviral.2017.02.009.28232248"/>
</results>
